vTv Therapeutics (VTVT) Total Current Liabilities (2014 - 2026)

vTv Therapeutics has reported Total Current Liabilities for 13 years, with the latest figure at $6.9 million in Q1 2026.

• Quarterly Total Current Liabilities rose 59.43% year-over-year to $6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.9 million (up 59.43% YoY) and the FY2025 annual result came in at $6.6 million, up 27.81% from the prior year.
• Total Current Liabilities advanced to $6.9 million in Q1 2026 per VTVT's latest filing, from $6.6 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $12.7 million in Q1 2022 and troughed at $4.3 million in Q1 2025.
• A 5-year average of $8.1 million and a median of $7.7 million in 2022 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities surged 146.03% in 2022, then tumbled 51.62% in 2025.
• Over 5 years, Total Current Liabilities stood at $7.7 million in 2022, then soared by 37.77% to $10.6 million in 2023, then plunged by 51.07% to $5.2 million in 2024, then climbed by 27.81% to $6.6 million in 2025, then advanced by 3.61% to $6.9 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $6.9 million, $6.6 million, and $10.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.